ArticleInternational journal of clinical and experimental medicine2015
Promising potency of retinoic acid-poly(ethylene glycol)-thiol gold nanoparticle conjugates for cervical cancer treatment.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hybrid AuNPs-3MPS-MTX nanosystem and its evaluation for treating cervical cancer and melanoma.Nanoscale advances · 2023Article
- Vitamin A and Retinoids in Bladder Cancer Chemoprevention and Treatment: A Narrative Review of Current Evidence, Challenges and Future Prospects.International journal of molecular sciences · 2021Review
- Drug Delivery Approaches for the Treatment of Cervical Cancer.Pharmaceutics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the effect of synthesized retinoic acid-poly(ethylene glycol)-thiol gold nanoparticle conjugates on cervical carcinoma cells. Cervical cancer is the major cause of deaths for the women of reproductive age in the developing countries. Compared to retinoic acid, the nanoparticle conjugates exhibited better activity against cervical carcinoma. Selective delivery of gold nanoparticle conjugates to estrogen receptor positive cervical cancer cells with 6-fold enhanced drug potency was observed. Transfer of gold nanoparticles was found to be dominated by estrogen ligand and receptor. It appeared that retinoic acid nanoparticle conjugates were selectively taken and retained by the estrogen receptor alpha present in the plasma membrane. Thus IC50 values for RA-PEG-SH were significantly improvedon nanoparticle ligation. Cells on treatment with RA-PEG-SH-AuNPsshowed growth inhibition at 12 and 24 h after incubation. The IC50 for RA in RA-PEG-SH-AuNPs after 12 and 24 h were 3 and 1 μM, respectively. Thus, the use of RA nanoparticle conjugates can be a better strategy for cervical carcinoma treatment.
Indexed as
Identifiers
26379840PMC4565223What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.